Following Protest, FDA Accepts Pharmacyclics’ Xcytrin NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO tells “The Pink Sheet” DAILY data slated for release at upcoming medical conferences could further support approval.
You may also be interested in...
Pharmacyclics Taps Little-Used Regulatory Pathway For Xcytrin NDA
Firm’s decision to “file over protest” asks FDA to review NDA that received “refuse to file” letter in February.
Advisory Committee Votes Favorably On Dendreon’s Prostate Cancer Vaccine
Though questions remain, majority of members find Provenge has “substantial evidence” of efficacy.
Pharmacyclics Eyes Priority Review For NSCLC Treatment
CEO tells “The Pink Sheet” DAILY of the firm’s plan for detailing and ex-U.S. commercialization.